Evidence map›Paper›PMID 36883877›Full record

ArticleActa dermato-venereologica2023

Tumour Suppressor Neuron Navigator 3 and Matrix Metalloproteinase 14 are Co-expressed in Most Melanomas but Downregulated in Thick Tumours.

Olga Bugaeva, Pilvi Maliniemi, Wenche S Prestvik, Eeva Leivo, Nicolas Kluger, Alexander Salava, Sanna Virtanen, Kirsi Jäntti, Olli Saksela, Kaisa Lehti and 3 more

Open access · goldAbstract read
In one paragraph

Article in Acta dermato-venereologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Olga Bugaeva1Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Research Program Unit, University of Helsinki, Helsinki, Finland. olga.i.bugaeva@gmail.com.
Pilvi Maliniemi1Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, .
Wenche S PrestvikDepartment of Biomedical Laboratory Science, Norwegian University of Science and Technology, Trondheim, Norway.
Eeva LeivoDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Nicolas KlugerDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Alexander SalavaDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Sanna VirtanenClinical Research Institute HUCH, Helsinki, Finland.
Kirsi JänttiDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Olli SakselaDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Kaisa Lehti1Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Research Program Unit, University of Helsinki, Helsinki, Finland.
Paula KujalaFimlab Laboratoriot Ltd, Tampere, Finland.
Kaj KrohnClinical Research Institute HUCH, Helsinki, Finland.
Annamari RankiDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
University of Helsinki · FIHelsinki University Hospital · FIFimlab (Finland) · FINorwegian University of Science and Technology · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is a highly metastatic tumour originating from neural crest-derived melanocytes. The aim of this study was to analyse the expression of neuron navigator 3 (NAV3) in relation to membrane type-1 matrix metalloproteinase MMP14, a major regulator of invasion, in 40 primary melanomas, 15 benign naevi and 2 melanoma cell lines. NAV3 copy number changes were found in 18/27 (67%) primary melanomas, so that deletions dominated (16/27 of samples, 59%). NAV3 protein was found to be localized at the leading edge of migrating melanoma cells in vitro. Silencing of NAV3 reduced both melanoma cell migration in 2-dimensional conditions, as well as sprouting in 3-dimensional collagen I. NAV3 protein expression correlated with MMP14 in 26/37 (70%) primary melanomas. NAV3 and MMP14 were co-expressed in all tumours with Breslow thickness < 1 mm, in 11/23 of mid-thickness tumours (1-5 mm), but in only 1/6 samples of thick (> 5 mm) melanomas. Altogether, NAV3 number changes are frequent in melanomas, and NAV3 and MMP14, while expressed in all thin melanomas, are often downregulated in thicker tumours, suggesting that the lack of both NAV3 and MMP14 favours melanoma progression.

Indexed as

Matrix Metalloproteinase 14MelanomaHumansImmunohistochemistryMelanocytesNeuronsMatrix Metalloproteinase 14

Identifiers

PMID36883877
PMCPMC10010123
OpenAlexW4323534864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.